spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:   ARIES 

 HSMN NewsFeed - 10 Mar 2021
Luminex Submits Joint SARS-CoV-2 and Flu/RSV Respiratory Panel to FDA for Emergency Use Authorization
Diagnostics FDA
 HSMN NewsFeed - 4 Mar 2021
Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG(R) Respiratory Panel Test Including SARS-CoV-2
Diagnostics FDA Regulatory
 HSMN NewsFeed - 22 Jul 2020
Luminex Files for Emergency Use Authorization for Expanded NxTAG Respiratory Panel Test Including SARS-CoV-2
Diagnostics FDA
 HSMN NewsFeed - 20 Jul 2020
Luminex Receives FDA Emergency Use Authorization for COVID-19 Antibody Test
Diagnostics FDA
 HSMN NewsFeed - 6 Apr 2020
Luminex Receives FDA Emergency Use Authorization for ARIES(R) SARS-CoV-2 Assay to Detect Virus Responsible for COVID-19 Disease
Diagnostics FDA
 HSMN NewsFeed - 13 Mar 2020
Luminex Provides Update on SARS-CoV-2 Validation Testing Efforts
Diagnostics
 HSMN NewsFeed - 19 Nov 2018
FDA Approves AEMCOLO(TM) (rifamycin), the First Antibiotic Approved for the Treatment of Travelers' Diarrhea in Over a Decade
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 25 Oct 2018
Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results
Diagnostics FDA Product Launch
 HSMN NewsFeed - 13 Oct 2017
Olympus Announces Continued Expansion of Its GI Endoscopic Device Line with ESD Innovations
Devices Gastroenterology Product Launch
 HSMN NewsFeed - 24 Jul 2017
Luminex Corporation Receives FDA Clearance for ARIES C. difficile Assay
Diagnostics FDA
 HSMN NewsFeed - 28 Jun 2017
Luminex Corporation Receives CE-IVD Mark for ARIES(R) Norovirus Assay
Diagnostics Regulatory
 HSMN NewsFeed - 3 May 2017
Luminex Corporation Receives FDA Clearance for ARIES Bordetella Assay
Diagnostics FDA
 HSMN NewsFeed - 16 May 2016
Luminex Corporation Signs Definitive Agreement to Acquire Nanosphere, Inc.
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 7 Oct 2015
Luminex Corporation Receives FDA Clearance for ARIES(R) System and ARIES(R) HSV 1&2 Assay
Diagnostics FDA
 HSMN NewsFeed - 28 Oct 2008
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals
 HSMN NewsFeed - 29 May 2008
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2007
Gilead Announces New LetairisTM (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2007
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
Gilead Submits New Drug Application To U.S. FDA for Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 7 Sep 2006
Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2006
BioAlliance Pharma Strengthens International Capabilities in Key Legal, IP and Regulatory Departments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2006
New Data Shows CRESTOR(R) Helped African American, Hispanic American and South Asian American Patients Significantly Lower LDL-C and Achieve Cholesterol Goals
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 May 2006
Ambrisentan Phase 3 ARIES-2 PAH Data Presented At ATS 2006 -- San Diego
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 17

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 17 additional stories matching:
ARIES
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.